Ideas in this flowchart

• Engineered TYK2 dependence enables myeloid-selective IL-10 receptor agonism.
• Engineered TYK2 dependence provides the basis for myeloid selectivity.
• The approach uses a tetravalent nanobody-based myeloid-selective IL-10 receptor agonist.
• The agonist recapitulates IL-10’s potent suppression of myeloid immune cells.
• Monocytes are among the suppressed cell types.
• Macrophages are among the suppressed cell types.
• Dendritic cells are among the suppressed cell types.
• The agonist avoids stimulation of T cells.